We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rapid Diagnostic System to Detect Neonatal Sepsis Within Hours

By LabMedica International staff writers
Posted on 12 Feb 2025
Print article
Image: The rapid diagnostic to detect neonatal sepsis can provide results within hours versus days (Photo courtesy of 123RF)
Image: The rapid diagnostic to detect neonatal sepsis can provide results within hours versus days (Photo courtesy of 123RF)

Neonatal sepsis is a life-threatening condition caused by bloodstream infections in newborns under 28 days old. Due to their underdeveloped immune systems, newborns are particularly vulnerable to infections. Each year, an estimated 2.5 million neonates or infants under one month of age die from sepsis, with the greatest impact in low- and middle-income countries. Since neonatal sepsis can progress quickly, it requires immediate intervention with IV fluids and antibiotics. For every hour treatment is delayed, the risk of death from neonatal sepsis increases by 7.6%. Researchers are now advancing a robust, cost-effective device that detects neonatal sepsis by utilizing advanced digital imaging and signal processing, delivering results within hours instead of days.

AstraDx (Beverly, MA, USA) is developing a technology that aims to detect pathogens, identify the specific pathogen, and perform phenotypic antimicrobial susceptibility testing (AST) directly from whole blood, producing results in just four hours. The company has been awarded a USD 3 million grant by the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X, Boston, MA, USA) to demonstrate the feasibility of its device for detecting neonatal sepsis. AstraDx’s innovative approach, which uses small blood samples and leverages advanced digital imaging and signal processing to identify pathogens and antimicrobial resistance in hours instead of days, could mark a significant advancement in neonatal sepsis diagnostics. This technology could revolutionize clinical decision-making, enabling rapid, targeted treatment for critically ill patients and contributing to the global fight against antimicrobial resistance.

“Our system for diagnosing bloodstream infections for even the worst pathogens is designed to be easy to use and affordable for populations worldwide, including underserved populations,” said Fran White, CEO of AstraDx. “We are committed to meeting the challenge of emerging, highly antibiotic-resistant superbugs. Rapid ID and AST specifically for neonates, addresses the need for better life-saving treatment for this especially vulnerable population.”

Related Links:
AstraDx 
CARB-X

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest
New
Calprotectin Assay
Fecal Calprotectin ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.